| 1 |
34240438 | Fingerprint loss during combination therapy using osimertinib and anlotinib: A case report. | 2022 Feb |
1 |
| 2 |
35251994 | Case Report: Benefits of a NSCLC Patient With EGFR A289G/F287_G288insHA cis Mutations From Immunotherapy in Combination With Antiangiogenesis and Chemotherapy and Sequential Treatment of EGFR-TKI. | 2022 |
2 |
| 3 |
35530305 | Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib. | 2022 |
1 |
| 4 |
31957251 | Cost-effectiveness of icotinib versus whole-brain irradiation with or without chemotherapy in EGFR-mutant NSCLC patients with brain metastases. | 2021 Apr |
1 |
| 5 |
33382908 | Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations. | 2021 May |
1 |
| 6 |
33516270 | LncRNA APCDD1L-AS1 induces icotinib resistance by inhibition of EGFR autophagic degradation via the miR-1322/miR-1972/miR-324-3p-SIRT5 axis in lung adenocarcinoma. | 2021 Jan 30 |
3 |
| 7 |
33734432 | First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. | 2021 Mar 18 |
1 |
| 8 |
33776479 | The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer. | 2021 |
3 |
| 9 |
33835358 | Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutation. | 2021 Oct |
5 |
| 10 |
33835620 | Complete remission following icotinib administration in an advanced ectopic thymic carcinoma patient harbouring the EGFR exon 19 deletion. | 2021 Jul |
1 |
| 11 |
33853674 | Correction to: LncRNA APCDD1L-AS1 induces icotinib resistance by inhibition of EGFR autophagic degradation via the miR-1322/miR-1972/ miR-324-3p-SIRT5 axis in lung adenocarcinoma. | 2021 Apr 14 |
1 |
| 12 |
34255422 | Icotinib alone or with bevacizumab as first-line therapy in Chinese patients with advanced nonsquamous non-small cell lung cancer and activating EGFR mutations: A retrospective study. | 2021 Sep |
3 |
| 13 |
34280355 | Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. | 2021 Sep |
3 |
| 14 |
34312304 | Icotinib Induces Mechanism-Based Inactivation of Recombinant Human CYP3A4/5 Possibly via Heme Destruction by Ketene Intermediate. | 2021 Oct |
2 |
| 15 |
34590035 | EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma. | 2021 Jul |
1 |
| 16 |
34673645 | Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China. | 2021 |
2 |
| 17 |
34743246 | Synergistic inhibitory effect of berberine and icotinib on non-small cell lung cancer cells via inducing autophagic cell death and apoptosis. | 2021 Dec |
1 |
| 18 |
34770832 | Icotinib, Almonertinib, and Olmutinib: A 2D Similarity/Docking-Based Study to Predict the Potential Binding Modes and Interactions into EGFR. | 2021 Oct 24 |
3 |
| 19 |
34917992 | Response to Icotinib Plus Chemotherapy in Pulmonary Atypical Carcinoid Harboring the EGFR L858R Mutation: A Brief Report. | 2021 Dec |
1 |
| 20 |
35273907 | The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer. | 2021 |
1 |
| 21 |
31692291 | Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multi-center study. | 2020 Jan |
2 |
| 22 |
31828849 | Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study. | 2020 Feb |
1 |
| 23 |
31934888 | Icotinib: efficacy in different solid tumors and gene mutations. | 2020 Mar |
6 |
| 24 |
32000711 | Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer. | 2020 Jan 30 |
2 |
| 25 |
32047787 | Durable response to pulsatile icotinib for central nervous system metastases from EGFR-mutated non-small cell lung cancer: A case report. | 2020 Jan 26 |
2 |
| 26 |
32060099 | Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial. | 2020 Jul 1 |
1 |
| 27 |
32226300 | Bisdemethoxycurcumin Enhances the Sensitivity of Non-small Cell Lung Cancer Cells to Icotinib via Dual Induction of Autophagy and Apoptosis. | 2020 |
6 |
| 28 |
32606956 | Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial. | 2020 |
2 |
| 29 |
32642157 | Non-significant efficacy of icotinib plus pleurodesis in epidermal growth factor receptor positive mutant lung cancer patients after malignant pleural effusion drainage compared to icotinib alone. | 2020 May |
2 |
| 30 |
32776462 | Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I and G724S: A case report and literature review. | 2020 Sep |
1 |
| 31 |
32953862 | Lung adenocarcinoma harboring rare epidermal growth factor receptor L858R and V834L mutations treated with icotinib: A case report. | 2020 Sep 6 |
2 |
| 32 |
32982275 | Three Novel EGFR Mutations (750_758del, I759S, T751_I759delinsS) in One Patient with Metastatic Non-Small Cell Lung Cancer Responding to Osimertinib: A Case Report. | 2020 |
1 |
| 33 |
33026449 | Icotinib With Concurrent Radiotherapy vs Radiotherapy Alone in Older Adults With Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Randomized Clinical Trial. | 2020 Oct 1 |
2 |
| 34 |
33116624 | Durable Response to Osimertinib in a Chinese Patient with Metastatic Lung Adenocarcinoma Harboring a Rare EGFR L858R/D761Y Compound Mutation. | 2020 |
1 |
| 35 |
33173309 | A Novel MYH9-RET Fusion Occurrence and EGFR T790M Loss as an Acquired Resistance Mechanism to Osimertinib in a Patient with Lung Adenocarcinoma: A Case Report. | 2020 |
1 |
| 36 |
33181408 | Design, synthesis and antitumor activity of icotinib derivatives. | 2020 Dec |
1 |
| 37 |
33219256 | Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib. | 2020 Nov 20 |
1 |
| 38 |
33414999 | Potential predictive value of serum targeted metabolites and concurrently mutated genes for EGFR-TKI therapeutic efficacy in lung adenocarcinoma patients with EGFR sensitizing mutations. | 2020 |
1 |
| 39 |
33489802 | Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study. | 2020 Dec |
3 |
| 40 |
29972257 | Suppressed expression of Cbl-b by NF-κB mediates icotinib resistance in EGFR-mutant non-small-cell lung cancer. | 2019 Feb |
4 |
| 41 |
30736738 | Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report. | 2019 Feb 8 |
3 |
| 42 |
30862147 | [Clinical effect of icotinib in treatment of elderly advanced non-small cell lung cancer patients with EGFR mutations]. | 2019 Feb 23 |
1 |
| 43 |
30953548 | Sequence-dependent synergistic cytotoxicity of icotinib and pemetrexed in human lung cancer cell lines in vitro and in vivo. | 2019 Apr 5 |
1 |
| 44 |
31033571 | Icotinib plus osimertinib overcome epidermal growth factor receptor 19del/T790 M/C797S/V834L quadruplet resistance mutation in a patient with non-small cell lung cancer. | 2019 May 5 |
1 |
| 45 |
31045832 | Clinical characterization of icotinib-induced chemoresistance in erlotinib-treated lung adenocarcinoma patient with EGFR mutations: A case report. | 2019 May |
2 |
| 46 |
31064887 | Effectiveness of EGFR-TKIs in a Patient with Lung Adenocarcinoma Harboring an EGFR-RAD51 Fusion. | 2019 Aug |
26 |
| 47 |
31106124 | A comparison of EGFR mutation status in tissue and plasma cell-free DNA detected by ADx-ARMS in advanced lung adenocarcinoma patients. | 2019 Apr |
1 |
| 48 |
31131689 | De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors. | 2019 |
1 |
| 49 |
31142691 | Combined Treatment with Triptolide and Tyrosine Kinase Inhibitors Synergistically Enhances Apoptosis in Non-small Cell Lung Cancer H1975 Cells but Not H1299 Cells through EGFR/Akt Pathway. | 2019 Aug 1 |
1 |
| 50 |
31173177 | Quinalizarin, a specific CK2 inhibitor, can reduce icotinib resistance in human lung adenocarcinoma cell lines. | 2019 Aug |
9 |